重庆智翔金泰生物制药股份有限公司 2025年度业绩快报

Financial Performance Summary - In 2025, the company achieved total operating revenue of 230.72 million yuan, representing a growth of 666.65% compared to the previous year [1] - The net profit attributable to the parent company was a loss of 536.22 million yuan, which is a 32.74% reduction in losses year-on-year [1][2] - The net profit attributable to the parent company after deducting non-recurring gains and losses was a loss of 579.22 million yuan, with a 27.99% reduction in losses compared to the previous year [1] Asset and Equity Status - As of the end of the reporting period, the company's total assets amounted to 2.99 billion yuan, a decrease of 4.87% from the same period last year [2] - The equity attributable to the parent company was 1.58 billion yuan, down 25.49% year-on-year [2] Revenue and Profit Analysis - The significant increase in operating revenue is attributed to the expansion of the sales market for the company's first commercialized product, the Saliqi monoclonal antibody injection, which saw steady growth in sales [2] - The revenue from the licensing and commercialization agreement for the GR1803 injection also positively impacted the company's net profit during the reporting period [2] Drug Development Update - The company announced that its GR1802 injection for adult seasonal allergic rhinitis has passed the primary endpoint in Phase III clinical trials and the new drug application has been accepted by the National Medical Products Administration (NMPA) [4][5] - GR1802 is a fully human anti-IL-4Rα monoclonal antibody that specifically binds to the IL-4Rα on cell surfaces, inhibiting Th2-type inflammatory responses [6] Clinical Trials and Future Prospects - The GR1802 injection has multiple indications in clinical trials, including chronic rhinosinusitis with nasal polyps and chronic spontaneous urticaria, with various stages of clinical trials ongoing [6] - As of the announcement date, only two other drugs targeting the same receptor have been approved for marketing in China [7]